201 related articles for article (PubMed ID: 25214642)
1. Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma.
Cerci JJ; Györke T; Fanti S; Paez D; Meneghetti JC; Redondo F; Celli M; Auewarakul C; Rangarajan V; Gujral S; Gorospe C; Campo MV; Chung JK; Morris TP; Dondi M; Carr R;
J Nucl Med; 2014 Oct; 55(10):1591-7. PubMed ID: 25214642
[TBL] [Abstract][Full Text] [Related]
2. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
[TBL] [Abstract][Full Text] [Related]
3. Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography.
Vishnu P; Wingerson A; Lee M; Mandelson MT; Aboulafia DM
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):631-636. PubMed ID: 28684378
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
[TBL] [Abstract][Full Text] [Related]
5. Direct comparison of visual and quantitative bone marrow FDG-PET/CT findings with bone marrow biopsy results in diffuse large B-cell lymphoma: does bone marrow FDG-PET/CT live up to its promise?
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Acta Radiol; 2015 Oct; 56(10):1230-5. PubMed ID: 25387723
[TBL] [Abstract][Full Text] [Related]
6. Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma.
Carr R; Fanti S; Paez D; Cerci J; Györke T; Redondo F; Morris TP; Meneghetti C; Auewarakul C; Nair R; Gorospe C; Chung JK; Kuzu I; Celli M; Gujral S; Padua RA; Dondi M;
J Nucl Med; 2014 Dec; 55(12):1936-44. PubMed ID: 25429159
[TBL] [Abstract][Full Text] [Related]
7. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy.
Teagle AR; Barton H; Charles-Edwards E; Dizdarevic S; Chevassut T
Acta Radiol; 2017 Dec; 58(12):1476-1484. PubMed ID: 28382828
[TBL] [Abstract][Full Text] [Related]
8. [Diagnostic value of FDG-PET in the detection of bone marrow involvement in patients with diffuse large B-cell lymphoma].
Zhang X; Fan W; Lin XP
Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):832-5. PubMed ID: 19176040
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of bone marrow infiltration detected by PET-CT in newly diagnosed diffuse large B cell lymphoma.
Liang JH; Sun J; Wang L; Fan L; Chen YY; Qu XY; Li TN; Li JY; Xu W
Oncotarget; 2016 Apr; 7(14):19072-80. PubMed ID: 26919239
[TBL] [Abstract][Full Text] [Related]
10. PET/CT Scanner and Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Diffuse Large B-Cell Lymphoma.
El Karak F; Bou-Orm IR; Ghosn M; Kattan J; Farhat F; Ibrahim T; Jreige M; El Cheikh J; Haidar M
PLoS One; 2017; 12(1):e0170299. PubMed ID: 28099514
[TBL] [Abstract][Full Text] [Related]
11. Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma.
Hong J; Lee Y; Park Y; Kim SG; Hwang KH; Park SH; Jeong J; Kim KH; Ahn JY; Park S; Park J; Lee JH
Ann Hematol; 2012 May; 91(5):687-695. PubMed ID: 22008868
[TBL] [Abstract][Full Text] [Related]
12. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
[TBL] [Abstract][Full Text] [Related]
13. The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study.
Alzahrani M; El-Galaly TC; Hutchings M; Hansen JW; Loft A; Johnsen HE; Iyer V; Wilson D; Sehn LH; Savage KJ; Connors JM; Gascoyne RD; Johansen P; Clasen-Linde E; Brown P; Villa D
Ann Oncol; 2016 Jun; 27(6):1095-1099. PubMed ID: 27002106
[TBL] [Abstract][Full Text] [Related]
14. Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma.
Adams HJ; Nievelstein RA; Kwee TC
Blood Rev; 2015 Nov; 29(6):417-25. PubMed ID: 26113144
[TBL] [Abstract][Full Text] [Related]
15. Biopsy remains indispensable for evaluating bone marrow involvement in DLBCL patients despite the use of positron emission tomography.
Saiki Y; Tomita N; Uchida A; Uemura Y; Suzuki Y; Hirakawa T; Kato M; Hoshikawa M; Kawano T; Nakamura N; Miura I; Arai A
Int J Hematol; 2021 May; 113(5):675-681. PubMed ID: 33515158
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow evaluation in initial staging of lymphoma: 18F-FDG PET/CT versus bone marrow biopsy.
Cortés-Romera M; Sabaté-Llobera A; Mercadal-Vilchez S; Climent-Esteller F; Serrano-Maestro A; Gámez-Cenzano C; González-Barca E
Clin Nucl Med; 2014 Jan; 39(1):e46-52. PubMed ID: 23640215
[TBL] [Abstract][Full Text] [Related]
17. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma.
Kim TM; Paeng JC; Chun IK; Keam B; Jeon YK; Lee SH; Kim DW; Lee DS; Kim CW; Chung JK; Kim IH; Heo DS
Cancer; 2013 Mar; 119(6):1195-202. PubMed ID: 23212736
[TBL] [Abstract][Full Text] [Related]
18. The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell lymphoma and baseline bone marrow involvement.
Jackson AE; Smeltzer JP; Habermann TM; Jones JM; Burnette B; Ristow K; Wiseman GA; Macon WR; Nowakowski GS; Witzig TE
Am J Hematol; 2014 Sep; 89(9):865-7. PubMed ID: 24823914
[TBL] [Abstract][Full Text] [Related]
19. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY
Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438
[TBL] [Abstract][Full Text] [Related]
20. Standardized uptake value for (18)F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with diffuse large B-cell lymphoma.
Akkas BE; Vural GU
Rev Esp Med Nucl Imagen Mol; 2014; 33(3):148-52. PubMed ID: 24094371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]